Armstrong Juggles Reformulating Primatene Mist, Pushing To Sell Existing Inventory
This article was originally published in The Tan Sheet
Armstrong Pharmaceuticals plans to submit in the fourth quarter an NDA to FDA for an OTC asthma inhaler reformulated without chlorofluorocarbon as a propellant. The House Energy and Power Subcommittee proposes allowing the firm to sell its remaining inventory of CFC-containing Primatene Mist.
You may also be interested in...
The House Energy and Power Subcommittee July 18 will discuss draft legislation that would require EPA to allow sales of the remaining inventory of Armstrong Pharmaceutical’s CFC-propelled epinephrine inhalers, Primatene Mist.
Lawmakers seek to restore the availability of Primatene Mist while the absence of an alternative OTC asthma remedy persists.